Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616558 | 0.93 | ABCG2 (0.41) | MAPK1L3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL28452635 | 0.93 | ABCG2 (0.41) | MAPK1L3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL21815478 | 0.82 | MEN1 (0.47) | MAPK1HSD17B10L3MBTL1MAPTRAB9A | |
| SCHEMBL28380826 | 0.81 | TSHR (0.39) | MAPK1HSD17B10L3MBTL1MAPTRAB9A | |
| SCHEMBL28354485 | 0.81 | TSHR (0.39) | MAPK1HSD17B10L3MBTL1MAPTRAB9A | |
| SCHEMBL4420431 | 0.81 | L3MBTL1 (0.42) | MAPK1L3MBTL1MAPTRAB9AATM | |
| SCHEMBL21219198 | 0.81 | ALDH1A1 (0.41) | MAPK1L3MBTL1MAPTRAB9AATM | |
| SCHEMBL27208962 | 0.81 | MAPT (0.40) | MAPK1HSD17B10L3MBTL1MAPTRAB9A | |
| SCHEMBL28541140 | 0.80 | ALDH1A1 (0.43) | MAPK1L3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL28313554 | 0.80 | MAPT (0.41) | L3MBTL1MAPTRAB9AATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221656-A | Compounds useful for the treatment of gastrointestinal disorders | 阿德利克斯股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-110267944-B | Compounds useful for the treatment of gastrointestinal disorders | 阿德利克斯股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116789636-A | Bifunctional compound, preparation method, pharmaceutical composition and application thereof | 北京康辰药业股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116478093-A | Molecular probe for targeting interferon gene stimulus factor, labeling method and application | 厦门大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-116284404-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116173232-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116059201-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059202-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059394-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | US | disclosed |
| CN-109562170-B | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-3860991-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | Emory University (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113209306-A | Antibody drug conjugates with cell permeable BCL-XL inhibitors | 艾伯维公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-111620862-A | BCL-XL-inhibitory compounds and antibody drug conjugates including the same | 艾伯维公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111620861-A | BCL-XL inhibitory compound having low cell permeability and antibody drug conjugate including the same | 艾伯维公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2020072955-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | HAVCR2, HMBS, HDGF | MAPK1 2189/4885HSD17B10 1720/4885L3MBTL1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.